I can't see why it is disappointing. Cohort A are people who are not getting any great benefit from Keytruda so it is game over for them. Efti improves their chances by a third. And cohort B start out as high risk patients(probably deemed not to have a great chance on Keytruda alone (although I don't know the details), they get a 50% response rate. And it is safe. This looks good for the next phase of the trial.
I can't see why it is disappointing. Cohort A are people who are...
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.5¢ |
Change
0.020(7.02%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 31.0¢ | 29.0¢ | $1.171M | 3.900M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 101067 | 30.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 8068 | 2 |
View Market Depth
| Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
